INCR Stock Analysis: Buy, Sell, or Hold?
INCR - Intercure Ltd. Ordinary Shares
$0.75
-0.03 (-3.67%)
▼
5d:
+2.04%
30d:
-12.35%
90d:
-18.13%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 20, 2026
Get Alerted When INCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INCR shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: INCR shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: INCR is currently trading at $0.74, which is considered oversold relative to its 30-day fair value range of $0.75 to $0.83.
Technical Outlook: Technically, INCR is in a strong downtrend. Immediate support is located at $0.72, while resistance sits at $0.80. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $33.56 (+4239.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INCR is in a strong downtrend. Immediate support is located at $0.72, while resistance sits at $0.80. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $33.56 (+4239.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.75 -
$0.83
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 4239.3% below Wall St target ($33.56)
Fair Price Analysis
30-Day Fair Range
$0.75 -
$0.83
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.72
Resistance Level
$0.80
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.94
Wall Street Target
$33.56
(+4239.3%)
Revenue Growth (YoY)
3.4%
Earnings Growth (YoY)
-84.7%
Profit Margin
-29.2%
Share & Embed Analysis
Last updated: April 02, 2026 12:08 PM ET
Data refreshes hourly during market hours. Next update: 1:08 PM
Data refreshes hourly during market hours. Next update: 1:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 65 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$38 | 64 BUY |
